Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Galusic, Davor, Basic-Kinda, Sandra, Pijuk, Andela, Milunovic, Vibor, Dreta, Barbara, Franjic, Neven, Coha, Bozena, Sincic-Petricevic, Jasminka, Gacina, Petar, Pejsa, Vlatko, Lucijanic, Marko, Aurer, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668548/
https://www.ncbi.nlm.nih.gov/pubmed/36407092
http://dx.doi.org/10.1097/HS9.0000000000000807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668548/
https://www.ncbi.nlm.nih.gov/pubmed/36407092
http://dx.doi.org/10.1097/HS9.0000000000000807

Ejemplares similares